Saghmos Therapeutics' is developing ST-62516 to prevent cardiorenal complications of contrast-induced acute kidney injury. We are poised to initiate a Phase 3 study for ST-62516 in 2021.
Contrast-induced acute kidney injury is a multi-billion dollar market opportunity, with no pharmacological agents approved to prevent or treat it.